Article

Sirion, AVR promote retinal and meibomian gland health

Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR's new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit).

Tampa, FL

-Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR’s new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit). Sirion’s sales force will promote actively the two products as well as provide sampling for the company’s line of topical drops to treat dry eye.

The oral nutritional supplement aims to address the factors that threaten long-term eye and general health. These factors include oxidation, inflammation, and neovascularization, which also are risks in patients with macular degeneration and diabetic retinopathy. The supplement includes a combination of antioxidants, anti-inflammatories, and anti-angiogenics that include fish oil omega-3 fatty acids, vitamin D, green tea extract, and vitamin E.

Meibomitis is a precursor to meibomian gland dysfunction. The condition is characterized by excess bacteria in the eye lid margins, increased vascularization of the lids, and loss of normal meibomian gland anatomy and function, which contribute to decreased quality and quantity of meibomian lips, tear-film lipid layer deficiency, and increased tear-film evaporation. The convenience kit includes doxycycline (75 mg), an omega-3 supplement with optimized flaxseed/fish oil blend (TheraTears Nutrition), and a portable warm compress system for symptom relief (iHeat).

“Sirion and [AVR] share a joint focus on healthy eyes for patients through clinical research and innovation in ocular disease,” said Jeffrey P. Gilbard, MD, founder, chief executive officer, and chief scientific officer of AVR, in a prepared statement. Dr. Gilbard also is a clinical assistant professor of ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center, Boston.

“Sirion’s resources and specialized sales force will be instrumental in helping AVR promote retinal and meibomian gland health and provide relief for dry-eye patients,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.